Skip to main content
Toggle navigation
Login
Home
Back
Favorite
0
Like
Facebook
Tweet
Session III: Urothelial Cancer
Debate: Cisplatin-Ineligible Patient with Advanced Urothelial Cancer with LN-only Metastasis and PD-L1 High Tumor - Carboplatin/Gemcitabine with Switch Maintenance Avelumab
Wednesday, March 9, 2022
2:15 PM – 2:22 PM
Debate Speaker(s)
Shilpa Gupta, MD
Taussig Cancer Institute, Cleveland Clinic Foundation